Reviva: A Beacon of Hope for Those Suffering with Mental Illnesses

Reviva (NASDAQ: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries. To learn more, visit: https://bit.ly/3YAo2Vr

Transcription:

Estimated that more than one in five U.S. adults live with a mental illness (57.8 million in 2021)

Introducing Reviva Pharmaceuticals (Nasdaq: RVPH)

Reviva's lead drug Brilaroxazine is expecting efficacy results for schizophrenia this year 2023!

Does Brilaroxazine become a beacon of hope everyone suffering from:
Bipolar Disorder TAM: $5.4 Billion
Major Depressive TAM: $15.9 Billion
Schizophrenia TAM: $7.9 Billion
ADHD TAM: $24.9 Billion
Idiopathic Pulmonary Fibrosis TAM: $5.9Billion